Xarelto

Quote

Anonymous

Guest
Few within Bayer realize that Xarelto is one of the main contributors to Bayer's profitability. Even fewer realize we have a US sales force (although small). All the hype and accolades in the new cardiopulmonary BU are going to the Adempas side. Not saying they aren't busting their butts to launch Adempas but Xarelto isn't selling itself. It's on a steep growth curve even with stiff competition and covering geographies 5x the size of our competitors. We seldom hear anything from our VP or FSD other than logistics. EC better start recognizing our hard work and results and align our salaries with industry standards, as was done for the other half of this BU. If not, some of his top producers will be ripe for the picking by Daiichi.
 




Anonymous said:
Few within Bayer realize that Xarelto is one of the main contributors to Bayer's profitability. Even fewer realize we have a US sales force (although small). All the hype and accolades in the new cardiopulmonary BU are going to the Adempas side. Not saying they aren't busting their butts to launch Adempas but Xarelto isn't selling itself. It's on a steep growth curve even with stiff competition and covering geographies 5x the size of our competitors. We seldom hear anything from our VP or FSD other than logistics. EC better start recognizing our hard work and results and align our salaries with industry standards, as was done for the other half of this BU. If not, some of his top producers will be ripe for the picking by Daiichi.
Click to expand...

It's Kogenate baby! That's were the money's at.
 








Anonymous said:
Few within Bayer realize that Xarelto is one of the main contributors to Bayer's profitability. Even fewer realize we have a US sales force (although small). All the hype and accolades in the new cardiopulmonary BU are going to the Adempas side. Not saying they aren't busting their butts to launch Adempas but Xarelto isn't selling itself. It's on a steep growth curve even with stiff competition and covering geographies 5x the size of our competitors. We seldom hear anything from our VP or FSD other than logistics. EC better start recognizing our hard work and results and align our salaries with industry standards, as was done for the other half of this BU. If not, some of his top producers will be ripe for the picking by Daiichi.
Click to expand...

Unless there is a stage there is no EC.
 




Bayer, you look like an amateur trying to play in the big leagues. So far your goal of creating a footprint in Cardiology is failing miserably as you continue to allow Janssen to call all the shots. We now have the additional confusion of working for Bayer without all the benefits of working for Janssen. Who would have ever thought a contract position would be better. Today's call is a prime example, discuss X and then move onto Invokana while we're still on the call! EC why do you continue to allow Janssen to lead us,??? From attending their calls, participating in their contests, to now attending their POA, instead of running our own which would allow us to focus solely on what we need to? We are merely following Janssen's orders. Ever notice how they refer to each other on calls by first name? We have no idea who all the voices are on the calls, yet no introductions are made. I can only imagine the wasted time at the upcoming meeting as we follow THEIR agenda, btw- my RSM still has no idea what's happening at the meeting but I've gotten some info from my Janssen rep. We're starting to be seen as an annoyance, someone to boss around, certainly not an equal partner. Their DMs expect us to attend their meetings and question our call plans, yet our RSM never holds a meeting because the areas are so large we can't get together. A POA with just Bayer would have been especially beneficial, with you leading us, not some Janssen person we don't know! Our geographies are ridiculously large in comparison to Janssen, requiring weekly overnight travel and yet we're not compensated for that, nice work/life balance rhetoric. We need leaders within Bayer!
 




Anonymous said:
Bayer, you look like an amateur trying to play in the big leagues. So far your goal of creating a footprint in Cardiology is failing miserably as you continue to allow Janssen to call all the shots. We now have the additional confusion of working for Bayer without all the benefits of working for Janssen. Who would have ever thought a contract position would be better. Today's call is a prime example, discuss X and then move onto Invokana while we're still on the call! EC why dor you continue to allow Janssen to lead us,??? From attending their calls, participating in their contests, to now attending their POA, instead of running our own which would allow us to focus solely on what we need to? We are merely following Janssen's orders. Ever notice how they refer to each other on calls by first name? We have no idea who all the voices are on the calls, yet no introductions are made. I can only imagine the wasted time at the upcoming meeting as we follow THEIR agenda, btw- my RSM still has no idea what's happening at the meeting but I've gotten some info from my Janssen rep. We're starting to be seen as an annoyance, someone to boss around, certainly not an equal partner. Their DMs expect us to attend their meetings and question our call plans, yet our RSM never holds a meeting because the areas are so large we can't get together. A POA with just Bayer would have been especially beneficial, with you leading us, not some Janssen person we don't know! Our geographies are ridiculously large in comparison to Janssen, requiring weekly overnight travel and yet we're not compensated for that, nice work/life balance rhetoric. We need leaders within Bayer!
Click to expand...

EC lead? Good one
 








Hire top performers, used to maxing out bonus plans and pay out entire division at 100% target, even though Bayer is raking it in as sales for X are GREAT!!! (Guess 300% listed on plan was just for show since no one is even close to making it and big deal that we aren't force ranked since we're all getting target)! Brilliant! Thanks for the demotivation and pay cut EC and GR! Great to hear about the promising future we're building, but good luck holding on to your performers. Enough talk!
 












EC can you explain to the field force why everyone received payouts around 100% for bonus. No one was even close to a top 200 or 300% payout. Seems to completely contradict other divisions and Bayer's pay for performance philosophy. The complicated payout tables with all the levels of payout mean nothing and will become even more difficult to hit 2% growth per quarter. We need a leader that makes our interests a top priority. This isn't a Janssen issue, Bayer has the ability and responsibility to make this right and yet no acknowledgement. You've got people working their tails off, without receiving a high level of compensation for results and this is not something that should be swept under the rug, it's too important!!
 




The discrepancy between the high levels paid out to top Adempas reps (down payments on homes) versus the other half of the division, actually driving profits is unjustified!
 




The whole division is a sham starting at the top. One is a rental sales force that is constantly bring told it's not, and the other was just bought, errr, collaborating with Merck. Bayer does not have the stomach for cardiology (especially in the US) any more
 




I always get a laugh when a newly created sales force that really has not even sold a dime of Xarelto attempts to take the credit for a very successful drug that they didn't even launch and feels entitled to not only take the credit of others, in this case Janssens launch & work, but proceeds to complain that the bonus payout is not enough. Really, what percent of the "main contributor" to Bayer have you really sold. What a joke.
 




























Top Bottom
Back
Quote